Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736798 | 0.90 | GRIN1 (0.35) | GRIN1GRIN2BIDH1 | |
| SCHEMBL1157005 | 0.90 | GRIN1 (0.35) | GRIN1GRIN2BIDH1ADRA2AADRA1A | |
| SCHEMBL12637716 | 0.86 | TAAR1 (0.35) | ADRA2AADRA1A | |
| SCHEMBL3668508 | 0.86 | P2RX7 (0.33) | — | |
| SCHEMBL3671318 | 0.82 | TAAR1 (0.39) | GRIN2BADRA2ACYP2D6ADRA2BADRA1A | |
| SCHEMBL3672714 | 0.75 | IDH1 (0.32) | IDH1 | |
| SCHEMBL12637702 | 0.75 | CFB (0.33) | GRIN1GRIN2BGMNNCYP1A2CYP3A4 | |
| SCHEMBL3670063 | 0.75 | TAAR1 (0.36) | GMNNCYP1A2CYP3A4HTR1AADRA2A | |
| SCHEMBL3411854 | 0.74 | ADRA2A (0.37) | GMNNCYP1A2CYP3A4HTR1AADRA2A | |
| SCHEMBL3669310 | 0.73 | CFB (0.36) | ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242753-B1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-2242753-B1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8735399-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735399-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735399-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2240468-B1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN INC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362022-B2 | Selective subtype alpha 2 adrenergic agents and methods for use thereof | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2240468-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009091760-A1 | OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091759-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091759-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ALLERGAN, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206701-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | GRIN1 1586/4885GRIN2B 657/4885IDH1 4680/4885 |
| US-20110034517-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | GRIN1 1553/4885GRIN2B 653/4885IDH1 4684/4885 |
| US-20110105526-A1 | SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF | ADRB2, ADRA2C, ADRA2A | GRIN1 1580/4885GRIN2B 638/4885IDH1 4264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.